Navigation Links
Novel Human Tissue Transgenic Cancer Model May Offer Significant,Advance Toward Accurately Modeling Human Cancer

cancer."

About AVEO

AVEO is a private biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. The company utilizes its proprietary, genetically-defined cancer models for the identification and validation of novel cancer targets, and has begun to build an impressive portfolio of drug discovery and development programs around these high-value targets. AVEO also uses its Human Response Prediction(TM) Platform to identify genetic profiles that correspond with patient responsiveness. AVEO expects to commence Phase 2 clinical studies by mid-2007 for AV-951, its oral, second-generation VEGF receptor inhibitor and most advanced clinical program. AV-412, AVEO's EGFR/HER2 inhibitor, is currently in Phase I clinical trials. AV-299, a novel anti-HGF mAb, is currently being manufactured by XOMA under a supply agreement in anticipation of entering the clinic in early 2008. AVEO is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.aveopharma.com.

Contact

AVEO Pharmaceuticals, Inc.
JJ Owen, PhD, 617-299-5889
jjowen@aveopharma.com
or
Pure Communications
Adriana Jenkins, 617-744-1713


'"/>




Page: 1 2 3

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
(Date:10/22/2014)... Oct. 22, 2014 InVivo Therapeutics Holdings Corp. ... is revolutionizing spinal cord injury (SCI) treatment with ... to outperform in tissue regrowth in the spinal cord ... from an FDA approved polymer, the scaffold ultimately breaks ... to the human body. NVIV has recently attracted significant ...
(Date:10/22/2014)... REDWOOD CITY, Calif. , Oct. 22, 2014 ... ) today announced that results from the  IAP310 ... and Pain Medicine (RAPM), a peer-reviewed journal ... placebo-controlled, Phase 3 trial evaluating the safety and ... sufentanil sublingual tablet system (SSTS), for the treatment ...
(Date:10/20/2014)... MOUNTAIN VIEW, California , 20 de octubre ... un líder en el campo de la pulmonología ... en su Estudio RENEW, casi 3 meses antes ... prueba fundamental de exención de dispositivo de investigación ... y Medicamentos) para el sistema de espiral de ...
Breaking Medicine Technology:InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... HANOVER, N.J., Dec. 3, 2010 A newly published ... first-line treatment regimen including Zometa® (zoledronic acid) significantly improved ... diagnosed multiple myeloma patients compared with a regimen that ... of the effect of Zometa on bone complications (also ...
... Ariz., Dec. 3, 2010 Sunridge International (OTC Bulletin Board: ... Richard Smith will conduct a public conference call on Monday ... call is to provide a short update on the company,s ... the public and a question and answer period will be ...
Cached Medicine Technology:Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients 2Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients 3Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients 4Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients 5Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients 6Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients 7Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients 8
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... may be showing a genetic propensity for obesity as toddlers, ... been linked to increased body fat, but the same genes ... the researchers said. At 1 year, kids with these ... 3, however, these genes were linked to excessive weight gain, ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- Measures taken by ... in Ebola-ravaged Liberia may have limited the spread of ... report. The Firestone Natural Rubber Co. provides health ... residents of nearby densely populated communities. Between Aug. ... suspected Ebola cases among those 80,000 people. That incidence ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is offering ... a damaged mitral valve as the heart continues to ... Abbott Vascular , is designed to treat degenerative ... which the heart’s mitral valve leaflets fail to close ... left ventricle into the left atrium. The heart must ...
(Date:10/20/2014)... 20, 2014 hc1.com today announced ... cloud solution that enables healthcare organizations of all ... healthcare-specific customer relationship management (“CRM”) solution. , Designed ... needs of the healthcare industry, the hc1 Healthcare ... and patients by combining healthcare CRM, HIPAA-compliant collaboration, ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Sit and Slim ... 10 not to purchase or use Sit and Slim II ... Slim II is promoted as weight loss product on various ... from the market in 2010 for safety reasons, can significantly ...
Breaking Medicine News(10 mins):Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2
... , WASHINGTON, Oct. 13 Dr. Charmaine Yoest, President ... statement Tuesday regarding the Finance Committee vote on health care ... the four other committees with jurisdiction over health care reform ... language excluding abortion funding and coverage. In fact, the ...
... Speaker Nancy Pelosi issued the following statement today after ... insurance reform proposal. , "The Senate Finance Committee,s vote ... insurance reform bill to President Obama,s desk that will lower ... improve quality, and make health care affordable for the middle ...
... more pre-term infants survive, doctors see more babies with ... News) -- Increased survival of extremely pre-term infants has ... problems caused by abnormal development of blood vessels in ... looked at data on 506 extremely pre-term infants (born ...
... Parents today favor choices that have recently risen in popularity, ... parents like baby names that are not merely popular but ... of favor, a new study suggests. , The findings by ... that parental naming choices are influenced by trends in ways ...
... , LITTLE ROCK, Ark., Oct. 13 Keeping fit at a ... long and healthy life, according to new research co-authored by researcher ... the University of Warwick in the United Kingdom. , The ... September 30 and was based on data gathered since 1976 from ...
... 13 SRI International, an independent, nonprofit research ... been awarded a $1.55M U.S. Department of Defense/Prostate ... preclinical studies of SRI,s novel agents that have ... goal of the program is to discover treatments ...
Cached Medicine News:Health News:Eye Problems Increasing in Preemies 2Health News:Baby Names Prone to Boom-and-Bust Cycles 2Health News:For Older Adults, Good Nutrition and Exercise Are Key To Staying Healthy & Active 2Health News:For Older Adults, Good Nutrition and Exercise Are Key To Staying Healthy & Active 3Health News:SRI International Awarded a Department of Defense 'Laboratory-Clinical Transition' Grant to Advance SRI's Novel Anticancer Agents for Prostate Cancer Treatment 2Health News:SRI International Awarded a Department of Defense 'Laboratory-Clinical Transition' Grant to Advance SRI's Novel Anticancer Agents for Prostate Cancer Treatment 3
... Point-of Care Electronic Medical Record portion of ... documentation process and electronic patient record solution ... is both mobile and secure. Using a ... pentop technology with a stylus device, physicians ...
... Practice Partner Patient Records provides a ... both office and clinical efficiency, while ... Patient Records allows practices to replace ... feature set utilized nationwide by over ...
... Eyecare Advantage is one of ... Optometric practice management software is what ... ago! Compulink is among today's leaders ... Compulink's Eyecare Advantage integrates all the ...
... over 2,500 ophthalmologists nationwide, ... serve one of the ... in the country. With ... we are setting new ...
Medicine Products: